<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217096</url>
  </required_header>
  <id_info>
    <org_study_id>CSPAC-21</org_study_id>
    <nct_id>NCT04217096</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients</brief_title>
  <official_title>A Single-arm, Prospective Study to Evaluate the Efficacy and Safety of the Combination of Paclitaxel Liposome and S-1 as First-line Therapy in Treating Patients With Advanced Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is intended to investigate the efficacy and safety of the patients with
      confirmed advanced pancreatic cancer after treating with the combination of paclitaxel
      liposome plus S-1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allocation: Non-randomized Endpoint Classification: Efficacy/ Safety Study Intervention
      Model: single arm Masking: Open Lable Primary Purpose: Treatment
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>from the date of enrollment to the day of progression or death of any cause, whichever come first, assessed up to 10 months</time_frame>
    <description>To evaluate the Progression Free Survival of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>from the date of enrollment to the day of progression or death of any cause, whichever come first, assessed up to 10 months</time_frame>
    <description>To evaluate the Overall Response Rate of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>from the date of enrollmen to death of any cause or the end of this trial, whichever come first, assessed up to 10 months</time_frame>
    <description>To evaluate the overall survival of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>from the date of enrollment to the day of progression or death of any cause, whichever come first, assessed up to 10 months</time_frame>
    <description>To evaluate the disease control rate of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (Qol)</measure>
    <time_frame>from the date of enrollmen to death of any cause or the end of this trial, whichever come first, assessed up to 10 months</time_frame>
    <description>To evaluate the Quality of Life of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>from the date of enrollmen to death of any cause or the end of this trial, whichever come first, assessed up to 10 months</time_frame>
    <description>To evaluate the adverse events of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>paclitaxel liposome + S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel liposome at 175 mg/m^2 on day 1; S-1 at a dose according to the body surface area（＜1.25m^2，40mg Bid；1.25~1.5m^2,50mg Bid；＞1.50m^2,60mg Bid，d1-14，q3w）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel liposome</intervention_name>
    <description>Patients receive paclitaxel liposome 175 mg/m^2 (iv, 3h) on day 1 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic</description>
    <arm_group_label>paclitaxel liposome + S-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>Patients receive S-1 at a dose according to the body surface area（＜1.25m^2，40mg Bid；1.25~1.5m^2,50mg Bid；＞1.50m^2,60mg Bid）on days 1-14 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.</description>
    <arm_group_label>paclitaxel liposome + S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years and ≤75 years;

          2. the patients were confirmed as locally advanced or metastatic pancreatic cancer by
             histopathology;

          3. At least one measurable objective lesion was identified based on the RECIST1.1
             criteria;

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;

          5. The expected survival after surgery ≥3 months;

          6. Adequate liver/kidney/bone marrow function： Absolute neutrophil count (ANC)
             ≥1.5×10^9/L; Hemoglobin (Hgb) ≥9g/dL; Platelets (PLT) ≥100×10^9/L; Total bilirubin
             (TBIL) ≤1.5×ULN; Aspartate aminotransferase (AST) (serum glutamic oxaloacetic
             transaminase [SGOT]/ alanine aminotransferase (ALT) (serum glutamic pyruvate
             transaminase [SGPT]) ≤2.5×institutional upper limit of normal (ULN), or ≤5×ULN(hepatic
             metastases); Serum creatinine level is normal or creatinine clearance rate≥60
             mL/min/1.73 m^2.

          7. Subjects of child-bearing age must agree to take effective contraceptive measures
             during the study period; Serum or urine pregnancy tests must be negative for women of
             childbearing age 7 days before the start of chemotherapy、during the monthly treatment
             interval and after the last treatment;

          8. Signed informed content obtained prior to treatment.

        Exclusion Criteria:

          1. Symptomatic ascites;

          2. The target disease has cerebral metastasis;

          3. Previously received palliative chemotherapy or other palliative systemic therapy for
             advanced/metastatic pancreatic cancer;

          4. Previously received treatments based on paclitaxel liposomes or S-1, except for
             neoadjuvant therapy or adjuvant therapy (before and after R0/R1 excision), which was
             based on paclitaxel liposomes or S-1(the time of discontinuation of
             neoadjuvant/adjuvant chemotherapy before admission ≥6 months);

          5. Received surgical treatment ≤4 weeks before admission;

          6. Severe cancer-related cachexia and/or known weight loss &gt;15% occurred within one month
             before admission;

          7. The medical history and complications, which may affect patients' ability to
             participate in the study and their safety during the study, or interfere with
             explanation of the study results, for example: uncontrolled hypertension,
             cardiovascular and cerebrovascular diseases such as cerebrovascular accident (≤6
             months from the start of the study), myocardial infarction (≤less than 6 months from
             the start of the study), unstable angina pectoris, heart failure (≥2 grades) (NYHA
             functional score), severe arrhythmia requiring medication, metabolic dysfunction,
             severe renal insufficiency;

          8. Human immunodeficiency virus (HIV) or Hepatitis B Virus（HBV）、hepatitis C virus (HCV)
             positive with Liver dysfunction;

          9. Combined with other malignant tumors excepted pancreatic cancer within the first 5
             years of admission, excepted cured carcinoma in situ of cervix、basal cell carcinoma of
             the skin;

         10. History of allergy or hypersensitivity to any therapeutic ingredient;

         11. Patients with known active alcohol or drug abuse or dependence;

         12. Pregnancy, or women who are currently trying to conceive, or who are likely to have
             children and do not use contraceptives, or breastfeeding women;

         13. Participation in any trial drug treatment or another interventional clinical trial 30
             days before screening period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xian-Jun Yu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xian-Jun Yu, M.D., Ph.D.</last_name>
    <phone>+86 21 64175590</phone>
    <email>yuxianjun@fudanpci.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University; 270 Dong An Road, Shanghai 200032, China</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 31, 2019</study_first_submitted>
  <study_first_submitted_qc>January 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>January 1, 2020</last_update_submitted>
  <last_update_submitted_qc>January 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xian-Jun Yu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

